Previous 10 | Next 10 |
MyoKardia Reports Upbeat Phase 2a Clinical Data MyoKardia Inc. ( MYOK ) announced that its Phase 2a clinical trial of danicamtiv has yielded positive results. The company also discussed nonclinical data showing the novel mechanism of action of the drug candidate. Danicamtiv is MyoKar...
Marathon Patent Group (NASDAQ: MARA ) -14% . More news on: Marathon Patent Group, Inc., Fuwei Films (Holdings) Co., Ltd., Urban One, Inc., Stocks on the move, , Read more ...
Ziopharm Oncology (NASDAQ: ZIOP ) announces that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with Regeneron's (NASDAQ: REGN ) PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the treatment of recurrent...
BOSTON, June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combi...
BOSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June, M.D., as Chairman of its newly formed Scientific Advisor...
BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy: Promise of the Next Generation at the Ray...
ZIOPHARM Oncology (NASDAQ: ZIOP ) pushes higher after presenting data on the treatment of recurrent glioblastoma as part of the ASCO Virtual Scientific Program. More news on: ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
– Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile – – Controlled IL-12 in combination with PD-1 inhibitor has favorable safety profile and initial surviv...
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a consultant to Ziopharm and will continue to help guide the Compan...
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3,...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...